Products
Cetrorelix is commercially available as a powder and solvent for the preparation of a solution for injection (Cetrotide). It has been approved in many countries since 2003.
Structure and properties
Cetrorelix acetate is present in drugs as cetrorelix acetate. It is a decapeptide and a derivative of gonadotropin-releasing hormone (GnRH) produced by the hypothalamus, which differs from the natural hormone at positions 1, 2, 3, 6, and 10.
Effects
Cetrorelix (ATC H01CC02) inhibits the release of LH and FSH at the pituitary gland, thereby lowering estrogen and androgen concentrations. The effects are due to antagonism at GnRH receptors on the pituitary gland. In women, cetrorelix delays an LH surge and thus ovulation. Unlike GnRH agonists, administration of cetrorelix does not result in an initial increase in LH and FSH levels.
Indications
For prevention of premature ovulation in patients undergoing controlled ovarian stimulation followed by oocyte retrieval and assisted reproduction techniques.
Dosage
According to the SmPC. The drug is injected subcutaneously into the lower abdominal wall.
Contraindications
- Hypersensitivity
- Pregnancy and lactation
- In postmenopausal women
- Liver or kidney function limitations
For complete precautions, see the drug label.
Interactions
There is insufficient information on drug-drug interactions.
Adverse effects
The most common possible adverse effects include an increase in liver enzyme levels, ovarian hyperstimulation syndrome, and application site reactions.
